x Acta Scientific | International Open Library | Open Access Journals Publishing Group

Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 4 Issue 10

Emergency Approval of Favipiravir for Covid19 Infection in India

Subhrojyoti Bhowmick1*, Suddha Chatterjee2, Sanket Bandyopadhyay3, Soumyo Sarathi Ganguly4, Debarati Kundu5 and Sujit KarPurkayastha6

1Pharmacology, Certified in Patient Safety (Johns Hopkins University, USA), FISQua (U.K) and Associate Professor, Department of Pharmacology, KPC Medical College and Hospital, Kolkata, India
2Microbiology Student, St. Xavier’s College, Kolkata, India
3Biotechnology Student, Ramaiah College of Arts Science and Commerce, Bangalore, India
4Studying Integrated MSc-PhD in Chemical and Molecular Biology, School of Bioscient, Indian Institute of Technology, Kharagpur, India
5Clinical Research Coordinator at Peerless Hospitex Hospital and Research Center Ltd, Kolkata, India
6Department of Gastroenterology, Peerless Hospitex Hospital and Research Center Ltd, Kolkata, India

*Corresponding Author: Subhrojyoti Bhowmick, Pharmacology, Certified in Patient Safety (Johns Hopkins University, USA), FISQua (U.K) and Associate Professor, Department of Pharmacology, KPC Medical College and Hospital, Kolkata, India.

Received: August 24, 2020; Published: September 28, 2020

×

Abstract

  Novel Coronavirus or COVID-19 pandemic was first reported in Wuhan City, China in December 2019. According to WHO database the spread of infection has resulted in over 30 million infected people and over 943000 deaths worldwide till 19th September, 2020. Till date, unavailability of vaccines and specific antiviral drugs is a cause of grave concern. Worldwide,the search for the specific antiviral medication is underway. The Drug controller General of India (DCGI) has recently approved Favipiravir for emergency usage in mild to moderate Covid19 Indian patients. Favipiravir, an old antiviral drug marketed under the brand name Avigan by Fujifilm Toyama Chemical Co. Ltd, Japan, originally produced for Ebola Virus Disease has shown affirmative results in the treatment of COVID-19 across the globe. This article is an updated literature review conducted to determine the efficacy and safety of the drug Favipiravir (FPV) in general and in the treatment of COVID-19 across the globe. An extensive search was performed using keywords such as Favipiravir and SARSCoV-2 in platforms like Google Scholar and PubMed for the time period of 1st June 2000 to 31st July 2020. Common adverse effects of the drug include increased Liver enzymes and hyperuricaemia. Trials reported from Japan and Russia has proved the efficacy and safety of Favipiravir in Covid19 although published data from an Indian clinical trial is awaited. It appears to be a promising drug considering its oral formulation and safety profile, however, efficacy data from Indian patients are still awaited to recommend its wide spread usage.

Keywords: Favipiravir; COVID-19; Coronavirus

×

References

  1. Pruijssers AJ., et al. “Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice”. bioRxiv (2020).
  2. info. Coronavirus Update (Live): 17,341,192 Cases And 673,137 Deaths From COVID-19 Virus Pandemic – Worldometer (2020).
  3. Dong L., et al. “Discovering drugs to treat coronavirus disease 2019 (COVID-19)”. Drug Discovery and Therapy1 (2020): 58-60.
  4. Thacker T and Rajagopal D. “Indian Licensees Free to Price Remdesivir: Gilead”. The Economic Times (2020).
  5. Furuta Y., et al. “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase”. Proceedings of the Japan Academy, Series B7 (2017): 449-463.
  6. Varadharajan P. “Favipiravir Approved As Anti- COVID-19 Drug; DCGI Approves Influenza Treatment Drug For Covid-19 Treatment In India”. Inventiva (2020).
  7. Pharmaceutical Business review. CDSCO Approves Generics of Favipiravir And Remdesivir For Covid-19 (2020).
  8. da Silva Gabriel. “Protonation, Tautomerism, and Base Pairing of the Antiviral Favipiravir (T-705)” (2020).
  9. Harismah K and Mirzaei M. “Favipiravir: Structural Analysis and Activity against COVID-19”. Advanced Journal of Chemistry-Section B 2 (2020): 55-60.
  10. Choi KH. “Viral Polymerases”. In: Rossmann M., Rao V. (eds) Viral Molecular Machines. Advances in Experimental Medicine and Biology 726 (2012).
  11. Venkataraman S., et al. “RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution”. Viruses2 (2018): 76.
  12. Bruenn JA. “A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases”. Nucleic Acids Research7 (2003): 1821-1829.
  13. Hidehiro Sangawa., et al. “Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase”. Antimicrobial Agents and Chemotherapy 11 (2013): 5202-5208.
  14. Baranovich T., et al. “T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro”. Journal of Virology7 (2013): 3741-3751.
  15. Zhinan Jin., et al. “The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase”. PLoS One7 (2013): e68347.
  16. Furuta Y., et al. “Mechanism of Action of T-705 against Influenza Virus”. Antimicrobial Agents and Chemotherapy3 (2005): 981-986.
  17. Du YX and Chen XP. “Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection”. Clinical Pharmacology and Therapeutics 2 (2020): 242-247.
  18. Madelain V., et al. “Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials”. Clinical Pharmacokinetics8 (2016): 907-923.
  19. Mentré F., et al. “Dose regimen of favipiravir for Ebola virus disease”. The Lancet Infectious Diseases2 (2015): 150-151.
  20. Cai Q., et al. “Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study”. Engineering (2020).
  21. https://pubchem.ncbi.nlm.nih.gov/compound/Favipiravir#section=Toxicity-Summary
  22. Jin Z., et al. “Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs”. Antiviral Research 143 (2017): 151-161.
  23. Eikan Mishima., et al. “Uric Acid Elevation by Favipiravir, an Antiviral Drug”. Tohoku Journal of Experimental Medicine 2 (2020): 87-90.
  24. Russell CD., et al. “Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury”. Lancet 10223 (2020): 473-475.
  25. Murugan P. “How Effective Are The Drugs Approved To Treat COVID-19 Patients In India?” The Wire Science (2020).

 

×

Citation

Citation: Subhrojyoti Bhowmick., et al. “Emergency Approval of Favipiravir for Covid19 Infection in India". Acta Scientific Pharmaceutical Sciences 4.10 (2020): 120-126.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US